Literature DB >> 9527808

Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection.

S Leitzke1, W Bucke, K Borner, R Müller, H Hahn, S Ehlers.   

Abstract

The potential of liposome-encapsulated antibiotics for prolonging drug application intervals was investigated by using a murine model of chronic lethal Mycobacterium avium infection. Liposomal encapsulation of amikacin, but not of ciprofloxacin, resulted in high and sustained drug levels in infected tissues, exceeding the minimal inhibitory concentration for M. avium for at least 28 days. As a consequence, once-weekly and even once-monthly treatments with liposomal amikacin significantly reduced bacterial replication in infected tissues and extended the survival time of infected mice.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9527808      PMCID： PMC105436          DOI： 10.1128/AAC.42.2.459

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Mycobacterium avium complex in AIDS.

Authors:  L E Bermudez; C B Inderlied; L S Young
Journal:  Curr Clin Top Infect Dis       Date:  1992

2.  Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment.

Authors:  N Düzgüneş; D R Ashtekar; D L Flasher; N Ghori; R J Debs; D S Friend; P R Gangadharam
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

Review 3.  Mycobacterium avium complex infection.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

4.  The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).

Authors:  C R Horsburgh; R M Selik
Journal:  Am Rev Respir Dis       Date:  1989-01

5.  Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M H Cynamon; C E Swenson; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice.

Authors:  N Düzgüneş; V K Perumal; L Kesavalu; J A Goldstein; R J Debs; P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

7.  Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma.

Authors:  M E Jolley; S D Stroupe; C H Wang; H N Panas; C L Keegan; R L Schmidt; K S Schwenzer
Journal:  Clin Chem       Date:  1981-07       Impact factor: 8.327

8.  Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  M H Cynamon; C E Swenson; G S Palmer; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

9.  Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin.

Authors:  C E Swenson; K A Stewart; J L Hammett; W E Fitzsimmons; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

10.  Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides.

Authors:  L E Bermudez; A O Yau-Young; J P Lin; J Cogger; L S Young
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226
View more
  9 in total

1.  Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.

Authors:  D C Quenelle; J K Staas; G A Winchester; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Gamma interferon is essential for clearing Mycobacterium genavense infection.

Authors:  S Ehlers; E Richter
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

3.  Targeted delivery of amikacin into granuloma.

Authors:  Ana Montes-Worboys; Scott Brown; Doron Regev; Brendan F Bellew; Kamal A Mohammed; Ibrahim Faruqi; Parvesh Sharma; Brij Moudgil; Veena B Antony
Journal:  Am J Respir Crit Care Med       Date:  2010-08-06       Impact factor: 21.405

4.  Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.

Authors:  E L Barrow; G A Winchester; J K Staas; D C Quenelle; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 6.  Nanotechnology-Based Approach in Tuberculosis Treatment.

Authors:  Mohammad Nasiruddin; Md Kausar Neyaz; Shilpi Das
Journal:  Tuberc Res Treat       Date:  2017-01-22

Review 7.  Amikacin: Uses, Resistance, and Prospects for Inhibition.

Authors:  Maria S Ramirez; Marcelo E Tolmasky
Journal:  Molecules       Date:  2017-12-19       Impact factor: 4.411

Review 8.  Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.

Authors:  Afzal Hussain; Sima Singh; Sabya Sachi Das; Keshireddy Anjireddy; Subramanian Karpagam; Faiyaz Shakeel
Journal:  Curr Drug Deliv       Date:  2019       Impact factor: 2.565

Review 9.  Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.

Authors:  Fernanda Andrade; Diana Rafael; Mafalda Videira; Domingos Ferreira; Alejandro Sosnik; Bruno Sarmento
Journal:  Adv Drug Deliv Rev       Date:  2013-08-07       Impact factor: 15.470
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.